<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03889145</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAH-1301</org_study_id>
    <nct_id>NCT03889145</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drugs Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drugs&#xD;
      interaction between Telmisartan, Amlodipine and Hydrochlorothiazide in healthy male&#xD;
      volunteers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2013</start_date>
  <completion_date type="Actual">February 19, 2014</completion_date>
  <primary_completion_date type="Actual">February 19, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>t1/2</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>CL/F</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan 80mg</intervention_name>
    <description>Telmisartan 80mg</description>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine10mg</intervention_name>
    <description>Amlodipine 10mg</description>
    <arm_group_label>Telmisartan, Amlodipine</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25mg</description>
    <arm_group_label>Hydrochlorothiazide</arm_group_label>
    <arm_group_label>Telmisartan, Amlodipine, Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male volunteers aged 20 to 55 years&#xD;
&#xD;
          -  Subjects who have 17.5 ~ 30.5 kg/m2 body mass index (BMI) and body weight that is more&#xD;
             than 55kg&#xD;
&#xD;
          -  Subjects who have no congenital or chronic disease within the last 3 years and have no&#xD;
             pathological symptoms or findings as a result of medical examination.&#xD;
&#xD;
          -  Suitable subject who is determined by laboratory tests such as hematology tests, blood&#xD;
             chemistry, urinalysis test according to the characteristics of the drug and screening&#xD;
             tests such as electrocardiography(ECG) test.&#xD;
&#xD;
          -  Subject who fully understand the clinical trials after in-depth explanation given&#xD;
             prior to the clinical study, decided to join the clinical trials by their will and&#xD;
             signed consent form which approved by Chonbuk National University Hospital&#xD;
             Institutional Review Board(IRB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have a history of blood, kidneys, endocrine, respiratory,&#xD;
             gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or&#xD;
             allergic diseases that is clinically significant (Except untreated asymptomatic&#xD;
             seasonal allergies at the time of administration)&#xD;
&#xD;
          -  Subjects who have a history of gastrointestinal disease or gastrointestinal surgery&#xD;
             which can affect drug absorption.&#xD;
&#xD;
          -  Subjects who drink Alcohol &gt; 210g/week within 6 months prior to the screening.&#xD;
&#xD;
          -  Subjects who involved in other clinical trials within two months before the first dose&#xD;
             medication characters.&#xD;
&#xD;
          -  Subjects who show Systolic Blood Pressure ≤100 or ≥150 mmHg or Diastolic Blood&#xD;
             Pressure ≤60 or ≥100 mmHg at screening&#xD;
&#xD;
          -  Subjects who had alcohol or drug abuse within one year before the screening&#xD;
&#xD;
          -  Subjects who took medication of drug-metabolizing enzymes that are known to&#xD;
             significantly induce or inhibit within 30 days&#xD;
&#xD;
          -  Subjects who smoke 20 cigarettes or more a day&#xD;
&#xD;
          -  Subjects who take medicine within 10 days before the first investigational product&#xD;
             administration.&#xD;
&#xD;
          -  Subject who done the whole blood donation within two months or component blood&#xD;
             donation within 1 month within 1 month prior to the first dosing.&#xD;
&#xD;
          -  Subject who can increase risk due to clinical test and administration of drugs or has&#xD;
             severe grade / chronic medical, mental condition or abnormal laboratory result that&#xD;
             may interfere with the analysis of test results.&#xD;
&#xD;
          -  Subjects with serious history of hypersensitivity or allergy to investigational&#xD;
             product.&#xD;
&#xD;
          -  Subjects with severe hepatic impairment or Gallbladder Disease.&#xD;
&#xD;
          -  Subject with hereditary angioedema or a history of angioedema when treated with&#xD;
             ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker)&#xD;
             therapy&#xD;
&#xD;
          -  Subjects who take combination medication with aliskiren in Diabetic patient or&#xD;
             moderate to severe renal insufficient subjects (glomerular filtration&#xD;
             rate&lt;60mL/min/1.73m2)&#xD;
&#xD;
          -  Subjects with severe hepatic impairment&#xD;
&#xD;
          -  Subjects who have severe aortic stenosis&#xD;
&#xD;
          -  Subjects with acute or severe renal failure&#xD;
&#xD;
          -  Subjects with hyponatremia or hypokalemia&#xD;
&#xD;
          -  Subjects with Addison's disease&#xD;
&#xD;
          -  Subjects with hypercalcemia&#xD;
&#xD;
          -  Subjects who have galactose intolerance, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  Subjects who are unwilling or unable to comply with the Lifestyle guidelines described&#xD;
             in this protocol&#xD;
&#xD;
          -  Subject who are inadequate for this study to participate judged by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2019</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

